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Dear Editor,
Reductions in average relative chemotherapy dose intensity
(ARDI; i.e. administered compared with planned) compro-
mise patient outcomes [3], and a recent Belgian study
showed that survival for non-Hodgkin lymphoma (NHL)
patients receiving CHOP-21 was reduced when ARDI fell
below 90% [2]. We support these findings with similar data
from the UK Audit of Lymphoma Patients (n=78 patients
who received CHOP-21 chemotherapy in 1999–2000) and
from the combined Belgian and UK data (n=289) [4].
Patient, disease and treatment characteristics were similar
between the two studies, except that the UK patients were
younger (mean age ± SD was 55±15 years versus 63±
14 years) and fewer UK patients received colony stimulating
factor (CSF). First cycle CSF use was 4% in the UK study
compared to 25% in the Belgian study. During an average
time to death or censoring of 72 months, 35% of patients in
the UK study died. In the Belgian study, the average
observation time was 30 months, during which 31% of
patients died. After adjusting for the higher mean age of the
Belgian patients, Kaplan–Meier survival functions were
similar between the two populations (log-rank test stratified
by 10-year age groups, p=0.38).
Kaplan–Meier plots for patients with >90% ARDI versus
≤90% ARDI showed reduced survival for the patients with
≤90% ARDI (Fig. 1). A trend towards reduced survival was
apparent in the UK dataset alone (Fig. 1a; log-rank test-
based p=0.090). For the combined dataset, the effect was
statistically significant (p<0.001; Fig. 1b), as for the
Belgian data alone [2].
Potential predictors of reduced survival were assessed
using an extended Cox proportional hazards regression
model with robust standard errors allowing for clustering
by centre. Using the UK dataset, reduced survival was
significantly associated with a higher Ann Arbor disease
stage (hazard ratio (HR) at treatment initiation 2.59 per
stage increase by 1, 95% CI 1.45–4.66, p=0.001) and
showed a trend towards association with age (HR 1.02 per
year of age, CI 1.00–1.04, p=0.058) and RDI≤90% (HR
1.42, CI 0.88–2.28, p=0.146). Using the combined dataset,
reduced survival was associated with more advanced
disease stage (HR 2.00, CI 1.44–2.77, p<0.001), age (HR
1.03, 95% CI 1.01–1.05, p=0.002) and RDI≤90% (HR
1.77, CI 1.12–2.79, p=0.014). In both models, the strength
of the association with disease stage decreased over time.
Approximately 23% and 30% of UK and Belgian
patients, respectively, received ARDI≤90% and were,
therefore, at risk of reduced survival. There are many
factors that result in a decision to reduce or delay che-
motherapy, including local institutional practice. Particular-
ly relevant is the higher proportion of elderly patients in the
Belgian dataset; elderly patients are at high FN risk [1] and
often receive lower doses of chemotherapy [3]. Despite this
common practice, dose-dense CHOP-14 chemotherapy
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well tolerated in both young and elderly NHL patients [5, 6].
This study highlights the potential impact of receiving
ARDI≤90% on survival. While further investigation is
needed, delivering full chemotherapy dose intensity
remains an important goal in NHL patients who receive
CHOP-21 chemotherapy.
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Fig. 1 Kaplan–Meier survivor estimates by RDI for UK dataset alone
(a) and the combined UK and Belgian datasets (b). Asterisk Log-rank
test-based p values
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